Smurf1 Inhibits Osteoblast Differentiation, Bone Formation, and Glucose Homeostasis through Serine 148  by Shimazu, Junko et al.
ReportSmurf1 Inhibits Osteoblast Differentiation, Bone
Formation, and Glucose Homeostasis through
Serine 148Graphical AbstractHighlightsd Smurf1 inhibits osteoblast differentiation by targeting Runx2
for degradation
d This function of Smurf1 requires the presence of serine 148
(S148) in Smurf1
d S148 in Smurf1 in osteoblasts is also needed for targeting
InsR for degradation
d Smurf1 regulates glucose metabolism by regulating InsR
accumulation in osteoblastsShimazu et al., 2016, Cell Reports 15, 27–35
April 5, 2016 ª2016 The Authors
http://dx.doi.org/10.1016/j.celrep.2016.03.003Authors
Junko Shimazu, Jianwen Wei,
Gerard Karsenty
Correspondence
gk2172@columbia.edu
In Brief
Shimazu et al. identify Smurf1 as a
determinant of osteoblast differentiation
during the development of bone
formation and glucose homeostasis post-
natally by targeting Runx2 and InsR,
respectively, for degradation in
osteoblasts and demonstrates the
necessity of serine 148 of Smurf1 for
these functions.
Cell Reports
ReportSmurf1 Inhibits Osteoblast Differentiation,
Bone Formation, and Glucose Homeostasis
through Serine 148
Junko Shimazu,1 Jianwen Wei,1 and Gerard Karsenty1,*
1Department of Genetics & Development, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
*Correspondence: gk2172@columbia.edu
http://dx.doi.org/10.1016/j.celrep.2016.03.003SUMMARY
The E3 ubiquitin ligase Smurf1 targets the master
regulator of osteoblast differentiation, Runx2, for
degradation, yet the function of Smurf1, if any, during
osteoblast differentiation in vivo is ill defined. Here,
we show that Smurf1 prevents osteoblast differenti-
ation by decreasing Runx2 accumulation in osteo-
blasts. Remarkably, mice harboring a substitution
mutation at serine 148 (S148) in Smurf1 that prevents
its phosphorylation by AMPK (Smurf1ki/ki) display a
premature osteoblast differentiation phenotype that
is equally severe as that of Smurf1/ mice, as well
as a high bone mass, and are also hyperinsulinemic
and hypoglycemic. Consistent with the fact that
Smurf1 targets the insulin receptor for degradation,
there is, in Smurf1ki/ki mice, an increase in insulin
signaling in osteoblasts that triggers a rise in the
circulating levels of osteocalcin, a hormone that fa-
vors insulin secretion. These results identify Smurf1
as a determinant of osteoblast differentiation during
the development of bone formation and glucose ho-
meostasis post-natally and demonstrate the neces-
sity of S148 for these functions.
INTRODUCTION
The transcription factor Runx2 has many attributes of a master
regulator of osteoblast differentiation. In its absence, there
are no osteoblasts anywhere in the skeleton, and its haplo-
insufficiency, by delaying osteoblast differentiation in bone
formation through intramembranous ossification, results in a
cleidocranial dysplasia (CCD), a disease characterized by
open fontanelles and short clavicles (Ducy et al., 1997; Komori
et al., 1997; Lee et al., 1997; Mundlos et al., 1997; Otto et al.,
1997). Conversely, an increase in Runx2 activity, as seen in
mice and humans lacking one allele of Twist, results in cranio-
synostosis because of a premature osteoblast differentiation in
the skull, leading to early closure of the sutures (Bialek et al.,
2004).
Not surprisingly, given the paramount importance of this tran-
scription factor for skeletogenesis, the mechanisms regulatingThis is an open access article under the CC BY-Nthe accumulation of Runx2 in cells of the osteoblast lineage
have been intensively studied. Runx2 accumulation in osteo-
blast progenitor cells and differentiated osteoblasts is regulated
in part by ubiquitination, and several E3 ubiquitin ligases have
been implicated in targeting Runx2 for degradation (Jones
et al., 2006; Kaneki et al., 2006; Zhao et al., 2003). One of
them Smurf1, interacts with Runx2 and other proteins regulating
bone mass accrual such as Smad1, Smad5, MEKK2, and the
insulin receptor (InsR) (Wei et al., 2014; Yamashita et al., 2005;
Zhu et al., 1999). Consistent with these biochemical findings,
forced expression of Smurf1 in osteoblasts inhibits, whereas
deletion of Smurf1 in all cells favors, bone formation in adult
mice (Yamashita et al., 2005; Zhao et al., 2004). It has been pro-
posed that Smurf1 achieves these functions in part by targeting
MEKK2 for degradation (Yamashita et al., 2005). Surprisingly,
given the biochemical evidence indicating that Smurf1 favors
the degradation of Runx2, no loss-of-function study has yet ad-
dressed the role of Smurf1 as a regulator of osteoblast differen-
tiation in vivo.
A second important question regarding Smurf1 biology is to
identify a domain, if not a single amino acid, that would confer
to this protein the ability to target Runx2 for degradation in vivo.
This question is even more relevant in view of the demonstration
that, in vitro, Smurf1 must be phosphorylated by AMPK on serine
148 (S148) in order to trigger the degradation of Runx2 (Wei et al.,
2015). This raises the question of the biological importance of
this residue in the functions of Smurf1.
We have addressed the aforementioned questions by
analyzing Smurf1/ mice and mice harboring a mutated form
of Smurf1 in which S148 is mutated to alanine (Smurf1ki/ki).
We show here that Smurf1 inhibits osteoblast differentiation
through its ability to target Runx2 for degradation and that
this function requires the presence of S148. Remarkably,
Smurf1ki/ki mice are also hypoglycemic and hyperinsulinemic,
because S148 is needed for Smurf1 ability to target the InsR
for degradation. As a result, there is an accumulation of the
InsR in the bones of Smurf1ki/ki mice. This leads to an increase
in the circulating levels of the bioactive form of the bone-derived
hormone osteocalcin that favors insulin secretion and can
cause hypoglycemia (Ferron et al., 2010a; Lee et al., 2007).
These results define critical functions of Smurf1 in cells of the
osteoblast lineage throughout life and highlight the importance
of S148 for Smurf1 ability to target Runx2 and InsR for
degradation.Cell Reports 15, 27–35, April 5, 2016 ª2016 The Authors 27
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
RESULTS
Smurf1 Regulates Osteoblast Differentiation
To determine whether Smurf1 affects osteoblast differentiation
in vivo, we analyzed, in post-natal day (P) 4 and P10 Smurf1/
mice, two parameters that reflect the activity of Runx2 in cells
of the osteoblast lineage during development: the closure of su-
tures in the skull and the length of clavicles.
Alcian blue/alizarin red staining of skeletal preparations
showed that the clavicles of Smurf1/ mice were significantly
longer than those of wild-type (WT) mice (Figure 1A), and sagittal
sutures of Smurf1/ skulls showed evidence of craniosynosto-
sis (Figures 1B and 1C). Next, we analyzed, by in situ hybridiza-
tion, the expression of Bone sialoprotein (Bsp), a biomarker of
osteoblast differentiation (Bialek et al., 2004) in the calvarial
bones of embryonic day (E) 14.5 WT and Smurf1/ embryos.
The expression of Bsp was stronger in the calvarial bones of
E14.5 Smurf1/ than in those of WT embryos (Figure 1D). The
same was true for the expression of Bsp and of Osteocalcin
(Ocn), another osteoblast differentiation marker, in the femurs
of E14.5 Smurf1/ embryos, whether this was assayed by
qPCR or by in situ hybridization (Figures 1E–1G). As a negative
control in this experiment, we analyzed the expression of a1(I)
Collagen (a1(I)Col), which is not regulated by Runx2 in vivo
(Wei et al., 2015).
To link this premature osteoblast differentiation to an increase
in Runx2 accumulation, we analyzed the abundance of this tran-
scription factor in the skulls of Smurf1/ andWT littermates and
observed that Runx2 was more abundant in Smurf1/ than in
WT skulls (Figure 1H). This latter result explains the increase in
the expression of Ocn, a target of Runx2 (Ducy et al., 1997) (Fig-
ures 1E, 1G, and 1I). Taken together, these results established
that Smurf1 is a negative regulator of osteoblast differentiation
in vivo and suggested that this function occurs, in part, by target-
ing Runx2 for degradation.
S148 Is Necessary for Smurf1 Ability to Inhibit
Osteoblast Differentiation and Bone Formation
In vitro, the phosphorylation of Smurf1 by AMPK at S148 is
needed for its ability to target Runx2 for degradation (Wei et al.,
2015). Thus, we tested the importance of this residue for Smurf1
ability to inhibit osteoblast differentiation by analyzing mutant
mice harboring a S148A mutation in Smurf1 (Smurf1ki/ki) (Figures
S1A–S1C). A western blot analysis verified that the phosphoryla-
tion of Smurf1 at S148 was abolished in Smurf1ki/ki osteoblasts,
although Smurf1 accumulation was not affected (Figure 2A).
Alcian blue/alizarin red staining of skeletal preparations
showed that clavicles were significantly longer and sagittal
sutures of the skulls were more closed in Smurf1ki/ki than in
newborn WT mice (Figures 2B–2D). Accordingly, osteoblasts
isolated from Smurf1/ or Smurf1ki/ki mice formed more miner-
alized nodules than WT osteoblasts (Figure S2A). In vivo, Bsp
expression was stronger in the calvarial bones of E14.5
Smurf1ki/ki embryos than in those of WT embryos (Figure 2E).
The expression of Ocn started earlier, and the expression of
Bsp was stronger in the femurs of Smurf1ki/ki than in those of
E14.5 WT embryos, indicating that osteoblast differentiation
occurred earlier in Smurf1ki/ki embryos throughout the skeleton.28 Cell Reports 15, 27–35, April 5, 2016In contrast, no overt difference in the expression of a1(I)Col be-
tween E14.5 WT and Smurf1ki/ki embryos was noted (Figure 2F).
The expression of Ocn and Bsp was also significantly higher in
the femurs of E14.5 Smurf1ki/ki embryos than in those of WT em-
bryos when measured by qPCR (Figures 2G and 2H).
That Bsp and Ocn expression was higher in the femurs of
Smurf1ki/ki mice at P10 (Figures S2B and S2C) suggested that
this S148A mutation in Smurf1may affect bone biology post-na-
tally. Indeed, 2-month-old Smurf1ki/ki mice had a higher bone
mass and higher trabecular number thanWT littermates because
of an increase in their osteoblast number and bone formation
rate (Figures 2I–2L). These phenotypes could be traced, in
part, to an increase in the accumulation of Runx2 in Smurf1ki/ki
skulls (Figure 2M). To ascertain that the phosphorylation of
Smurf1 at S148 is needed to target Runx2 for degradation, we
performed a glutathione S-transferase (GST) pull-down assay
and observed that the interaction between Smurf1 and Runx2
that occurred upon phosphorylation of Smurf1 by AMPK was
abrogated when S148 was mutated to alanine. Accordingly,
forced expression of WT, but not S148A Smurf1, decreased
the accumulation of Runx2 in COS-7 cells (Figures 2N and 2O).
Taken collectively, these data establish the importance of S148
for Smurf1 ability to inhibit osteoblast differentiation and bone
formation.
Smurf1 Inhibits Osteoblast Differentiation by Targeting
Runx2 to Degradation
If S148 is required for Smurf1 inhibition of osteoblast differentia-
tion because it targets Runx2 for degradation, mutating S148 to
alanine in Smurf1 should increase Runx2 accumulation and
rescue, in part, the CCD phenotype seen in Runx2+/ mice (Ko-
mori et al., 1997; Otto et al., 1997). To test this hypothesis, we
analyzed Runx2+/;Smurf1ki/ki mice.
Alcian blue/alizarin red staining of skeletal preparations
showed a marked improvement of the CCD phenotype in
Runx2+/;Smurf1ki/ki, compared to that inRunx2+/mice (Figures
3A–3C), while a western blot verified that Runx2 accumulation
was increased in Runx2+/;Smurf1ki/ki skulls (Figure 3D). This in-
crease in Runx2 accumulation resulted in an improved osteo-
blast differentiation, as shown by the increased Ocn expression
in E15.5 Runx2+/;Smurf1ki/ki embryos, compared to Runx2+/
embryos (Figure 3E). Expression of Ocn and Bsp was also
significantly higher in the bones of Runx2+/;Smurf1ki/ki mice,
compared to those of Runx2+/ mice at P10 when measured
by qPCR (Figures 3F and 3G).
Hence, the ability of Smurf1 to target Runx2 for degradation
explains, to a large extent, why this E3 ubiquitin ligase inhibits
osteoblast differentiation. That the rescue of the CCD phenotype
was not complete in Runx2+/;Smurf1ki/kimice is consistent with
the notion that Smurf1 also acts through additional mechanisms
to prevent osteoblast differentiation, such as targeting MEKK2,
Smad1, and Smad5 for degradation (Yamashita et al., 2005;
Zhu et al., 1999).
S148 Is Needed for Smurf1 Ability to Regulate Glucose
Homeostasis
To determine whether S148 is necessary for the interaction
of Smurf1 with its other substrates, we focused on the InsR,
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Figure 1. Regulation of Osteoblast Differentiation by Smurf1 In Vivo
(A and B) Alcian blue/alizarin red staining of (A) clavicles and (B) skulls of P4 and P10 WT and Smurf1/ mice, respectively. Scale bar, 1 mm.
(C) Opening of sagittal sutures in P10 Smurf1/ and WT mice.
(D) In situ hybridization analysis of Bsp expression in calvarial bones of E14.5 Smurf1/ and WT embryos. Scale bar, 100 mm.
(E and F) qPCR analysis of (E) Ocn and (F) Bsp expression in femurs of E14.5 WT and Smurf1/ embryos (n = 5).
(G) In situ hybridization analysis of Ocn, Bsp, and a1(I)Col expression in femurs of E14.5 Smurf1/ and WT embryos. Scale bar, 100 mm.
(H) Runx2 accumulation in skulls of P10 WT and Smurf1/ mice.
(I) Expression of Runx2 in the femurs of P10 WT and Smurf1/ mice (n = 6). n.s., not significant.
Error bars indicate mean ± SEM. *p% 0.05; #p% 0.005 (compared to control), from Student’s t tests.
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Figure 2. Phosphorylation of Smurf1 at S148 Is Necessary for Smurf1 Ability to Regulate Osteoblast Differentiation In Vivo
(A) Western blot analysis of S148 phosphorylation in Smurf1 in WT and Smurf1ki/ki osteoblasts.
(B and C) Alcian blue/alizarin red staining of (B) clavicles and (C) skulls of P4 and P10 WT and Smurf1ki/ki mice, respectively. Scale bar, 1 mm.
(D) Opening of sagittal sutures in P10 Smurf1ki/ki and WT mice.
(E and F) In situ hybridization analysis of (E) Bsp in calvarial bones and (F)Ocn,Bsp, and a1(I)Col expression in femurs of E14.5WT and Smurf1ki/ki embryos. Scale
bar, 100 mm.
(G and H) qPCR analysis of (G) Ocn and (H) Bsp expression in femurs of E14.5 WT and Smurf1ki/ki embryos (n = 4–5).
(legend continued on next page)
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because both Smurf1/ mice and Smurf1ki/ki mice were hypo-
glycemic and hyperinsulinemic (Figures 4A–4C).
Following its phosphorylation by AMPK, WT—but not S148A
Smurf1—interacts readily with the InsR (Figure 4D), and forced
expression of WT—but not S148A Smurf1—decreased the
accumulation of InsR in COS-7 cells (Figure 4E). In vivo, the
accumulation of the InsR was higher in Smurf1/ and
Smurf1ki/ki than in WT bones. That the accumulation of the
InsRwas not affected in other insulin target tissues, such as liver,
white adipose tissue (WAT), and muscle in Smurf1/ and
Smurf1ki/ki mice (Figure 4F) is explained, in part, by the fact
that Smurf1 expression is markedly higher in bone than in the
liver, WAT, and muscle (Figure 4G).
Given these observations, we testedwhether the hypoglycemia
seen inSmurf1ki/kimice resulted, in part, froman increase in insulin
signaling in osteoblasts. Since insulin signaling in osteoblasts in-
hibits Osteoprotegerin (Opg) expression (Ferron et al., 2010a),
we used the expression of this gene in Smurf1ki/ki femurs as a
readout of insulin signaling in osteoblasts. In agreement with the
increased accumulation of the InsR in bone (Figure 4F), Opg
expressionwas decreased inSmurf1ki/ki femurs compared to con-
trol femurs (Figure 4H), whereasRankl expressionwas unchanged
(Figure 4I). This decrease inOpg expression provides an explana-
tion for the significant increase in the number of osteoclasts
observed in the bones of adult Smurf1ki/kimice (Figure 4J). This in-
crease in bone resorption parameters was not of sufficient ampli-
tudetocompensate for the increase inboneformationparameters.
As a result, Smurf1ki/kimice had a high bone mass (Figures 2I–2L).
Since bone resorption is the mechanismwhereby osteocalcin,
a hormone that favors insulin secretion, is activated bydecarbox-
ylation (Ferronet al., 2010a),wemeasured thecirculating levels of
undercarboxyated and bioactive osteocalcin in control and
Smurf1ki/kimice andobserved that circulating undercarboxylated
osteocalcin levels were approximately 3-fold higher in Smurf1ki/ki
mice than in control mice (Figure 4K). Such an increase in circu-
lating osteocalcin levels should lead to a hyperinsulinemia and
hypoglycemia as seen in Smurf1ki/ki mice (Figures 4B and 4C).
To demonstrate that this increase in osteocalcin activity contrib-
utes to the hypoglycemia observed in Smurf1ki/ki mice, we
analyzed Smurf1ki/ki mice lacking one allele of Ocn (Smurf1ki/ki;
Ocn+/). As shown in Figure 4L, blood glucose levelswere normal
inSmurf1ki/ki;Ocn+/mice. These results reveal the existence of a
Smurf1-InsR-osteoprotegerin-osteocalcin pathway taking place
in osteoblasts and contributing to glucose homeostasis.DISCUSSION
The mechanisms regulating Runx2 accumulation in osteoblast
progenitor cells have been a topic of intense investigation. This
has led to the identification, mostly on biochemical grounds, of(I–L) Bone histomorphometric analysis of L3 and L4 vertebrae of 2-month-old WT
(BV/TV). (J) Trabecular number (Tb.N). (K) Osteoblast number per tissue area (N
trabecular surface area (BFR/BS).
(M) Runx2 accumulation in the skulls of P10 WT and Smurf1ki/ki mice.
(N) GST pull-down assay showing interaction of Flag-Runx2 with GST-Smurf1 W
(O) Effect of the forced expression of WT or S148A Smurf1 on the accumulation
Error bars indicate mean ± SEM. *p% 0.05; #p% 0.005 (compared to control), fseveral E3 ubiquitin ligases that would trigger Runx2 for degra-
dation. Given the number of E3 ubiquitin ligases known to
interact with Runx2, one could fear that disrupting the interaction
of only one of them with Runx2 would not significantly hamper
osteoblast differentiation in vivo. Instead, our investigation
shows that deleting a single E3 ubiquitin ligase implicated in
Runx2 degradation Smurf1 results in an increase in Runx2 accu-
mulation, leading to a premature osteoblast differentiation during
embryonic development and increased bone formation post-na-
tally. Furthermore, we show that the majority of this function of
Smurf1 requires a single amino acid, S148, to be phosphorylated
by AMPK (Wei et al., 2015). These results highlight the impor-
tance of Smurf1 and of this particular residue in this molecule
in targeting Runx2 for degradation in vivo and regulating osteo-
blast differentiation.
The functions of Smurf1 in osteoblasts extend beyond osteo-
blast differentiation and bone formation, since, by favoring the
degradation of the InsR in osteoblasts, Smurf1 is a regulator of
circulating osteocalcin levels. This explains the existence of hy-
perinsulinemia and hypoglycemia in Smurf1ki/ki mice. Indeed,
Smurf1 regulates bone resorption and the production of the
active form of osteocalcin, a hormone that favors insulin secre-
tion (Lee et al., 2007). As it is the case for its ability to regulate
osteoblast differentiation, this function of Smurf1 requires the
presence of S148. Altogether, our results provide a deeper un-
derstanding of the molecular regulation of Runx2 accumulation
and of the endocrine functions of bone.
EXPERIMENTAL PROCEDURES
Mice Generation
To generate Smurf1Ki/+ mice, a mutation was introduced into a bacterial artifi-
cial chromosome (BAC) by recombineering, using the galK selection system
(Warming et al., 2005). In the first step, the galK cassette was inserted into a
BAC by homologous recombination, and clones were obtained through posi-
tive selection onminimal media plates onwhich galactose was the only carbon
source. The successful recombination was validated by PCR analysis. In the
second step, the galK cassette was substituted by double-stranded oligonu-
cleotides, with the modified base pair in the middle of the homology arms
flanking the galK casette. This step was achieved by negatively selecting
against the galK cassette by resistance to 2-deoxy-galactose (DOG) on plates
with glycerol as the carbon source. Clones in which the galK cassette is
replaced by a mutation of interest were identified by PCR and sequencing.
A frt-neo-frt (FNF) cassette was inserted upstream of the mutation and
retrieved into the pMCS-DTA vector by homologous recombination using
standard protocol. The targeting vector that was verified by PCR, diagnostic
digestions, and sequencing was electroporated into embryonic stem (ES)
cells, and positive ES cells were identified by PCR screening and sequencing.
Selected ES cells were injected in 129Sv/EV blastocysts to generate chimeric
mice. Chimeric mice were crossed to Gt(ROSA)26Sortm1(FLP1)Dym to remove
the neomycin-resistance cassette (Figures S1A–S1C).
Runx2+/mice were generated previously (Otto et al., 1997). Smurf1+/mice
were a generous gift of Dr. Jeff Wrana (University of Toronto) (Narimatsu et al.,
2009). All mice strains were maintained on a C57/129 mixed background,and Smurf1ki/ki female mice (n = 7). (I) Mineralized bone volume per total volume
.Ob/T.Ar). (L) The annual fractional volume of trabecular bone formed per unit
T or S148A after phosphorylation by AMPK.
of Runx2 in COS-7 cells.
rom Student’s t tests.
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Figure 3. Smurf1 Phosphorylation at S148 Is Necessary to Regulate RUNX2 In Vivo
(A) Alcian blue/alizarin red staining of skulls of P10 Runx2+/ and Runx2+/;Smurf1ki/ki mice. Scale bar, 1 mm.
(B) Area of the opening of skulls in P10 Runx2+/;Smurf1ki/ki and Runx2+/ mice.
(C) Alcian blue/alizarin red staining of clavicles of P10 Runx2+/ and Runx2+/;Smurf1ki/ki mice. Scale bar, 1 mm.
(D) Runx2 accumulation in skulls of P10 Runx2+/, Runx2+/;Smurf1ki/ki, and WT skulls.
(E) In situ hybridization analysis of Ocn and a1(I)Col expression in E15.5 WT, Runx2+/ , and Runx2+/;Smurf1ki/ki femurs. Scale bar, 100 mm.
(F and G) qPCR analysis of (F) Ocn and (G) Bsp expression in femurs of P10 WT, Runx2+/, and Runx2+/;Smurf1ki/ki mice (n = 3–4).
Error bars indicate mean ± SEM. *p% 0.05; #p% 0.005 (compared to control), from Student’s t tests.
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Figure 4. Phosphorylation of SMURF1 at S148 Is Necessary for Smurf1 Activity to Regulate InsR Degradation
(A and B) Blood glucose levels in (A) P10 WT and Smurf1/ mice and (B) P10 WT and Smurf1ki/ki mice (n = 9–13 per group).
(C) Circulating insulin levels in P10 WT and Smurf1ki/ki mice (n = 6). BDL, below detection limit.
(D) GST pull-down assay showing interaction of InsR with GST-Smurf1 WT or GST-Smurf1 S148A after AMPK phosphorylation.
(E) Effect of the overexpression of WT or S148A Smurf1 on the accumulation of InsR in COS-7 cells.
(F) Accumulation of the InsR in skull, liver, WAT, and muscle of P10 WT, Smurf1/, and Smurf1ki/ki mice.
(G) Expression of Smurf1 in liver, WAT, muscle, and skull of P10 WT mice.
(H and I) Expression of (H) Opg and (I) Rankl in the femurs of P10 WT and Smurf1ki/ki mice (n = 8). n.s., not significant.
(legend continued on next page)
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except for Runx2+/ mice, which were maintained on a C57 background. Lit-
termates were used as controls in all experiments. All procedures involving an-
imals were approved by CUMC IACUC and conform to the relevant regulatory
standards.
Cell Culture
Primary mouse calvaria osteoblasts were cultured as described previously
(Ducy and Karsenty, 1995). To determine the formation of mineralized nodules,
von Kossa staining was performed on osteoblasts cultured in differentiation
medium supplemented with 5 mM b-glycerophosphate and 100 mg/ml ascor-
bic acid for 7 days. To detect the S148 phosphorylation in Smurf1, osteoblasts
isolated from Smurf1ki/ki and WT pups were incubated overnight in glucose-
free KRH buffer (50 mM HEPES, pH 7.4, 136 mM NaCl, 4.7 mM KCl,
1.25 mM MgSO4, 1.25mM CaCl2, and 0.1% BSA) and followed by western
blot analysis.
DNA Transfection Experiments
Myc-Smurf1 WT and S148A plasmids were constructed by inserting a full-
length cDNA of mouse Smurf1WT or S148A into pcDNA 3.1/myc-His B vector
(Invitrogen).Myc-Smurf1WT or S148Awas co-transfected with Flag-Runx2 or
the human InsR cDNA expression constructs (Wei et al., 2014, 2015) in COS-7
cells. DNA transfection experiments were performed using Lipofectamin 2000
(Invitrogen), according to the manufacturer’s protocol.
Western Blot Analysis
Anti-Runx2 antibody (Santa Cruz Biotechnology), anti-b-Actin (Sigma), Anti-
Smurf1, and Anti-Phospho-Ser148 Smurf1 (GenScript) were used. Other
antibodies were obtained from Cell Signaling Technology. All western blot
analyses were repeated at least three times, with different samples.
Gene Expression Analysis
RNA sampleswere extracted using TRIzol reagent (Invitrogen). Using 2 mg total
RNA, cDNA preparation was carried out following standard protocols. The
cDNAs were used as templates for qPCR analyses using CFX-Connect
Real-Time PCR Detection System (Bio-Rad). Expression levels of each gene
analyzed by qPCR were normalized using GAPDH (glyceraldehyde-3-phos-
phate dehydrogenase) expression levels as an internal control. The sequences
of specific primers used in this study were previously described (Obri et al.,
2014).
Skeletal Preparation and Analysis
Alcian blue/alizarin red staining of the skeletal preparation was conducted
according to standard protocols (McLeod, 1980). Littermate controls were
analyzed in all experiments. Quantifications of the length of clavicles, as well
as the area of the opening of the skull, were made using ImageJ.
Bone Histomorphometry
This analysis was performed on L3 and L4 vertebrae of 2-month-old female
mice as described previously (Chappard et al., 1987; Parfitt et al., 1987).
Mineralized bone volume over the total tissue volume, osteoblast number
per tissue area as well as trabecular number, and bone formation rate per
bone surface were measured by conducting Von Kossa/van Gieson staining,
toluidine blue staining, and calcein double labeling, respectively. Osteoclast
parameters were measured by TRAP staining, followed by counterstain with
hematoxylin. Osteoclasts were defined as multinucleated dark red cells along
the bone surface. Histomorphometric analysis was performed using the
OsteoMeasure System (OsteoMetrics).
Biochemistry
ELISAs were performed according to the manufacturer’s instructions to mea-
sure mouse insulin (EZRMI-13K, Millipore) and undercarboxylated osteocalcin(J) Osteoclast number (N.Oc)/bone perimeter (B.Pm) (/mm) in 2-month-old WT a
(K) Serum levels of undercarboxylated osteocalcin in 2-month-old WT and Smur
(L) Blood glucose levels in P10 WT, Smurf1ki/ki, and Ocn+/;Smurf1ki/ki mice (n =
Error bars indicate mean ± SEM. *p% 0.05; #p% 0.005 (compared to control), f
34 Cell Reports 15, 27–35, April 5, 2016(Ferron et al., 2010b). For the AMPK phosphorylation assay, GST-Smurf1 and
GST-Runx2 constructs were generated and purified as previously described
(Ferron et al., 2013; Wei et al., 2015). The AMPK phosphorylation assay of
GST-Smurf1 WT and S148A was performed using a previously described
method (Wei et al., 2015).
GST Pull-Down Assay
GST-Smurf1 WT and GST-Smurf1 S148A were bound to glutathione agarose
beads (GE Healthcare) and blocked overnight at 4C in 5% BSA with end-
over-end mixing. Beads were washed with AMPK assay buffer five times,
and the AMPK phosphorylation assay was followed. Beads were washed
with binding buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 50 mM b-glyc-
erophosphate, 10% glycerol, 1% Tween-20, 1 mM EDTA, 25 mM NaF) five
times. Cell lysates of transfected COS-7 cells were incubated with 25 mg
of GST for 2 hr at 4C with end-over-end mixing. This mixture was centri-
fuged, and supernatants were mixed with GST-Smurf1 WT or S148A in
500 ml of binding buffer for 2 hr at 4C with end-over-end mixing. The mix-
tures were washed five times and analyzed by SDS-PAGE followed by
immunoblotting.
In Situ Hybridization
Tissues were fixed in 4% paraformaldehyde/PBS overnight at 4C and then
embedded in paraffin after serial dehydrations. Tissues were sectioned at
5 mm. In situ hybridization was performed using 35S-labeled riboprobe as
described previously (Ducy et al., 1997). The a1(I)Col, Bsp, and Ocn probes
were prepared as previously described (Takeda et al., 2001). Hybridizations
were performed overnight at 55C, andwashes were performed at 63C. Auto-
radiography was performed as previously described (Sundin et al., 1990), and
nuclei were counterstained with DAPI.
Statistics
All data are presented as mean ± SEM. In this paper, statistical analysis was
performed by unpaired Student’s t test. * denotes p % 0.05, and # denotes
p% 0.005 compared to control.
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